Simon Allen - Ambrx Biopharma Chief Business Officer
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
Insider
Simon Allen is Chief Business Officer of Ambrx Biopharma American since 2019.
| Age | 51 |
| Tenure | 5 years |
| Phone | 858 875 2400 |
| Web | https://ambrx.com |
Ambrx Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1862) % which means that it has lost $0.1862 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3723) %, meaning that it created substantial loss on money invested by shareholders. Ambrx Biopharma's management efficiency ratios could be used to measure how well Ambrx Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Ambrx Biopharma American currently holds 11.98 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Ambrx Biopharma American has a current ratio of 4.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ambrx Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Immix Biopharma | 49 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Peter Facchini | Enveric Biosciences | 60 | |
| Gabriel BA | Immix Biopharma | 37 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Nandan BS | Immix Biopharma | 62 | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| JD MBA | Immix Biopharma | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 |
Ambrx Biopharma American Leadership Team
Elected by the shareholders, the Ambrx Biopharma's board of directors comprises two types of representatives: Ambrx Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ambrx. The board's role is to monitor Ambrx Biopharma's management team and ensure that shareholders' interests are well served. Ambrx Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ambrx Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiao Le, Director | ||
| Daniel JD, President CEO | ||
| Feng Tian, Chairman of the Board, President, Chief Executive Officer | ||
| Jared Kelly, General VP | ||
| Robert Azzara, Vice Capital | ||
| Xiaowei Chang, Director | ||
| Katrin Rupalla, Independent Director | ||
| Sonja Nelson, Chief Financial Officer | ||
| Joy Yan, Chief Medical Officer | ||
| Shawn Zhang, Chief Officer | ||
| Olivia Ware, Independent Director | ||
| Ying Buechler, Chief Officer | ||
| Sonja CPA, Chief Officer | ||
| Andrew Aromando, Chief Officer | ||
| Simon Allen, Chief Business Officer | ||
| Renu MSc, Chief Officer | ||
| Chris Nolet, Independent Director | ||
| Sandra Aung, Chief Officer |
Ambrx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ambrx Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Shares Owned By Insiders | 2.09 % | |||
| Shares Owned By Institutions | 97.91 % | |||
| Number Of Shares Shorted | 1.16 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |